Skip to main content
. 2022 Sep 23;10(9):e004856. doi: 10.1136/jitc-2022-004856

Figure 2.

Figure 2

Depleting NAC1 decreases the glycolytic rate of melanoma cells. (A) Time series of ECAR measurements in WT and NAC1 KO B16-OVA cells by the Seahorse Metabolic Analyzer. (B) Time series of ECAR measurements in WT and NAC1 KO A2058 cells by the Seahorse Metabolic Analyzer. Data are represented as mean±SEM; n=6 wells per condition from two independent experiments. (C) Basal glycolysis rates of WT and NAC1 KO B16-OVA cells. (D) Maximum glycolysis rates of WT and NAC1 KO B16-OVA cells. (E) Basal glycolysis rates of WT and NAC1 KO A2058 cells. (F) Maximum glycolysis rates of WT and NAC1 KO A2058 cells. In (C–F), six wells per condition from two independent experiments; One-way ANOVA with multiple comparisons correction. (G) Quantification of relative glucose consumption in WT and NAC1 KO B16-OVA cells. (H) Quantification of lactase production in the supernatant of WT and NAC1 KO B16-OVA cells. (I) Quantification of relative glucose consumption in WT and NAC1 KO A2058 cells. (J) Quantification of lactase production in the supernatant of WT and NAC1 KO A2058 cells. **p≤0.01, ***p≤0.001. ANOVA, analysis of variance; ECAR, extracellular acidification rate; NAC1, nucleus accumbens-associated protein-1; OVA, ovalbumin.